Treatment Market is projected to grow at a healthy rate of around 13% by 2026. This growth is primarily driven by the ...
The U.S. Food and Drug Administration is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy ...
New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is ...
The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year ...
Researchers said a survey of U.S. adults found 72% say sleepiness sometimes, often or always gets in the way of their ...
Re-designed and re-imagined, the all-new A6 pairs sophistication and refined luxury with a dynamic, involving driving ...
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment ...
The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) (4).
Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...
The US FDA has tightened the use of a Duchenne muscular dystrophy gene therapy after two teenage patients died from acute ...
Elevidys now carries a black box warning for acute liver injury and failure, limiting its use to ambulatory patients aged four and older. The FDA's actions follow fatal liver failure reports in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback